Compare MRK & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRK | PFE |
|---|---|---|
| Founded | 2000 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | 155.0B |
| IPO Year | 1994 | 2013 |
| Metric | MRK | PFE |
|---|---|---|
| Price | $116.01 | $27.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 12 |
| Target Price | ★ $123.21 | $27.83 |
| AVG Volume (30 Days) | 9.7M | ★ 34.0M |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | 2.93% | ★ 6.46% |
| EPS Growth | ★ 8.01 | N/A |
| EPS | ★ 7.28 | 1.36 |
| Revenue | ★ $65,011,000,000.00 | $62,579,000,000.00 |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | ★ $15.93 | $19.58 |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $75.40 | $20.92 |
| 52 Week High | $125.14 | $27.94 |
| Indicator | MRK | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 53.01 |
| Support Level | $105.23 | $24.99 |
| Resistance Level | $125.14 | $27.67 |
| Average True Range (ATR) | 2.77 | 0.53 |
| MACD | -1.17 | -0.10 |
| Stochastic Oscillator | 19.08 | 50.00 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.